Table 2 |
|||
| Relationship between Ezrin protein overexpression and clinicopathological features of gastric adenocarcinoma | |||
| Clinical features | No. of cases | Strongly positive cases (%) | P-value |
| Age | |||
| <50 | 96 | 60 (62.5%) | NS |
| 51-69 | 181 | 92 (50.8%) | |
| ≥70 | 29 | 16 (55.2%) | |
| Gender | NS | ||
| Male | 164 | 102 (62.2%) | |
| Female | 113 | 66 (58.4%) | |
| Lauren Types | <0.05, a | ||
| Intestinal type | 117 | 77 (65.8%) | |
| Diffuse type | 139 | 85 (61.2%) | |
| Mixed type | 21 | 6 (28.6%) | |
| WHO’s Histological Types | NS | ||
| Well-diff. ade. | 85 | 42 (49.4%) | |
| Moderately-diff. ade. | 103 | 54 (52.4%) | |
| Poorly-diff. ade. | 59 | 50 (84.7%) | |
| Undifferentiated ade. | 5 | 3 (60.0%) | |
| Signet ring cell carcinoma | 9 | 5 (55.6%) | |
| Mucinous ade. | 16 | 14 (87.5%) | |
| LN Metastasis | <0.01 | ||
| Negative | 151 | 53 (35.1%) | |
| Positive | 126 | 115 (91.3%) | |
| Clinical Stage | <0.05, b | ||
| 0 | 39 | 14 (35.9%) | |
| IA | 47 | 12 (25.5%) | |
| IB | 51 | 23 (45.1%) | |
| II | 75 | 59 (78.7%) | |
| IIIA | 59 | 54 (91.5%) | |
| IV | 6 | 6 (100%) | |
| Disease Free Survival | <0.01 | ||
| ≥3 years | 152 | 53 (34.9%) | |
| <3 years | 125 | 115 (92.0%) | |
ade.: Adenocarcinoma; diff.: differentiated; NS: not significant. * Strongly positive: ++ and +++.
a: Intestinal & Diffuse types vs Mixed type.
b: Stage 0 + Stage IA + Stage IB vs Stage II + Stage IIIA + Stage IV.
Jin et al. Diagnostic Pathology 2012 7:135 doi:10.1186/1746-1596-7-135
